tpan.com: Test Positive Aware Network
Home

Brand Name: Emtriva

Common Name: emtricitabine (EMT) or FTC

Class: nucleoside analog (also called nucleoside reverse transcriptase inhibitor, NRTI or nuke)

Standard dose: One 200 mg capsule once-a-day, with no food restrictions (may be taken with or without food). The dosing frequency needs to be adjusted for people who have decreased kidney function. Take missed dose as soon as possible, but do not double up on your next dose

AWP: $347.11 / month

Manufacturer contact: Gilead Sciences, www.gilead.com,
1 (800) GILEAD5 (445–3235)

AIDS Treatment Information Service: 1 (800) HIV–0440 (448–0440)
Potential side effects and toxicity: Most common side effects include headache, diarrhea, nausea and rash. Skin discoloration observed as a darkening of the skin on the palms and the soles of the feet can occur and usually does not cause any symptoms. Rare but potentially fatal toxicity with all NRTIs is pancreatitis (inflammation of the pancreas), hepatomegaly with steatosis (enlarged, fatty liver) and lactic acidosis (accumulation of lactate in the blood and abnormal acid-base balance). Lactic acidosis has been seen in patients taking NRTIs but is more common and more severe in women, people who are obese and people who have been taking nukes for a long time; and more common in people with liver disease, but can occur in people without a history of liver damage. People with lactic acidosis may experience persistent fatigue, abdominal pain or distension, nausea/vomiting, and difficulty breathing or shortness of breath; and enlarged, fatty liver. Pancreatitis can be life-threatening and may cause pain in the stomach and back, along with nausea, vomiting and blood in the urine. Your physician will check for pancreatitis by checking for increased levels of amylase and lipase in the blood. Risks for pancreatitis include: higher than recommended doses of NRTIs, advanced HIV, and alcohol use. Children should be monitored carefully for pancreatitis.

Potential drug interactions: Epivir (3TC) and Emtriva (FTC) can lower the levels of Hivid, and should be avoided. No other significant drug interactions observed in clinical trials.

Tips: Emtriva (FTC) is called a “me-too” drug because of its similarity to Epivir (3TC); both drugs are associated with the M184V mutation (which suggests drug resistance). However, Emtriva remains in blood cells in excess of the 24-hour dosing interval. It also remains inside of the cell longer with a steady state intracellular mean half-life of the active drug of 39 hours.

Emtriva has demonstrated efficacy against HBV but is not currently approved to treat HBV. Worsening of hepatitis B (HBV) in people co-infected with HIV/HBV has occurred when Emtriva was discontinued. Patients co-infected with HIV/HBV who stop taking Emtriva should be closely followed by their physician. Available in a co-formulation with Viread, Truvada.


Doctor

Emtricitabine (FTC or EMT) is a nucleoside analog very similar to 3TC. It is a capsule dosed once-daily. It is very well tolerated but suffers the same weakness as 3TC: the M184V mutation. It is available as Emtriva or in the fixed-dose-combination tablet Truvada. It has been associated with some hyperpigmentation (darkening of the skin on the palms and soles) in some patients (more commonly African Americans). Like 3TC, Emtriva has activity against hepatitis B.—Chad J. Zawitz, MD


Activist

An Epivir “me too” drug. But Emtriva stays in your body longer, so it can be taken once a day. It is popular in a two drug co-formulation with Viread, as Truvada.—Nelson Vergel
More Publications
Positively Aware Positively Aware
Positively Aware en Espanol Positively Aware en Español
HIV Drug Guide HIV Drug Guide
Chicago HIV Services Directory Chicago HIV Services Directory
Subscribe Subscribe
Advertise Advertise
Editorial Policy Editorial Policy
   
More Links
Access the PA Archive Access the PA Archive
Download Acrobat Reader from Adobe Download Acrobat Reader from Adobe
Download Acrobat Reader from Adobe
Search TPAN or the Web Using Google Search TPAN or the Web Using Google
 
   
 

Ask a physician questions you may have about HIV/AIDS, and HIV/AIDS treatment. An American Academy of HIV Medicine (AAHIVM) credentialed HIV Specialist will answer your questions. A new column regularly featured in Positively Aware magazine, in collaboration with the AAHIVM, beginning with the March/April 2007 issue.

Send your questions in care of
Ask the HIV Specialist
5537 N. Broadway
Chicago, IL 60640
E-mail: aahivm@tpan.com.
 

This site contains HIV prevention messages that may not be appropriate for all audiences. Since HIV infection is spread primarily through sexual practices or by sharing needles, prevention messages and programs may address these topics. If you are not seeking such information or may be offended by such materials, please exit this website.

Este sitio del web contiene mensajes de la prevención del VIH que pueden no ser appropiados para todas las audiencias. Puesto que la infección del VIH es propagada sobre todo con prácticas sexuales o por compartiendo jeringas, los mensajes y los programas de la prevención pueden dirigirse a estos asuntos. Si usted no está buscando tal información o puede ser ofendido por tales materiales, salga por favor de este website.

  
 

Opinions expressed in Positively Aware, Positively Aware en Español, or tpan.com are not necessarily those of staff or membership of Test Positive Aware Network (TPAN), its supporters and sponsors, or distributing agencies. Information, resources, and advertising in Positively Aware, Positively Aware en Español, or tpan.com do not constitute endorsement or recommendation of any medical treatment or product.

TPAN recommends that all medical treatments or products be discussed thoroughly and frankly with a licensed and fully HIV-informed medical practitioner, preferably a personal physician.

Although Positively Aware, Positively Aware en Español, and tpan.com take great care to ensure the accuracy of all the information that it presents, Positively Aware, Positively Aware en Español, and tpan.com staff and volunteers, TPAN, or the institutions and personnel who provide us with information cannot be held responsible for any damages, direct or consequential, that arise from use of this material or due to errors contained herein.

  
 
[an error occurred while processing this directive]
Home   | About TPAN   | Publications   | Client Services   | Events   | Online Directory   | Resources   | Contact Us